Judith de Vos‐Geelen

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

Eva Versteijne, Mustafa Suker, Karin Groothuis et al. · Journal of Clinical Oncology · 2020 · 1.1K citations · Full text

Medicine, Oncology, Surgery +15

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

Anouk E.J. Latenstein, Lydia G. van der Geest, Bert A. Bonsing et al. · European Journal of Cancer · 2019 · 178 citations · Full text

Medicine, Oncology, Surgery +15

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

Quisette P. Janssen, Jacob L. van Dam, B. Bonsing et al. · BMC Cancer · 2021 · 170 citations · Full text

Medicine, Oncology, Surgery +16

Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial.

Geertjan van Tienhoven, Eva Versteijne, Mustafa Suker et al. · Journal of Clinical Oncology · 2018 · 161 citations

Medicine, Oncology, Surgery +17